Description

History / Background

ACE-031 is a synthetic peptide and modified form of a myostatin-blocking protein. It was developed by Acceleron Pharma with the goal of inhibiting myostatin, a naturally occurring protein that limits muscle growth. By blocking myostatin, ACE-031 was designed to promote muscle hypertrophy and improve muscle mass, making it a potential therapy for conditions such as muscular dystrophy, sarcopenia, and other muscle-wasting disorders.

Research on ACE-031 began in the late 2000s, with early clinical trials evaluating its safety, tolerability, and effectiveness in humans. Although results showed potential for increasing muscle mass, development of ACE-031 was halted after Phase 2 clinical trials due to safety concerns and adverse effects, preventing it from reaching approval or commercial use.

Research For:

The potential benefits of ACE-031 include:

1. Increased Muscle Mass
   ACE-031 is designed to inhibit myostatin, which can significantly promote muscle growth and increase lean muscle mass.

2. Improved Muscle Function
   In individuals with muscle-wasting conditions, ACE-031 may improve muscle performance, strength, and physical capability.

3. Potential Treatment for Muscle-Wasting Diseases
   ACE-031 showed early promise in research targeting muscular dystrophy and other disorders that result in severe muscle loss.

4. Enhanced Recovery
   By supporting muscle growth and strength, ACE-031 may potentially improve recovery speed following injuries or surgeries.

Important Considerations

• Regulatory Status

ACE-031 is not approved by the FDA or other regulatory agencies for human use. Its development was discontinued, and its long-term safety and efficacy remain unproven.

• Safety Concerns

Clinical trials identified potential adverse effects, which contributed to the termination of its development. The long-term risks—especially regarding chronic myostatin inhibition—are not well understood.

• Consultation with Healthcare Professionals

Individuals seeking muscle growth or recovery support should consult a healthcare professional for safe, evidence-based alternatives. Because ACE-031 is unregulated and discontinued, its use poses significant risks.